Fresenius has secured options on 37 biosimilars from WuXi Biologics, significantly expanding its biopharma ambitions through a development agreement. The deal comes as numerous high-selling biologics ...
The Basel region is one of the world’s leading life-science clusters. Pharmaceutical companies, biotech firms and research ...
Swedish biotech Alligator Bioscience has agreed to sell its CD40-targeting cancer immunotherapy mitazalimab to Canadian drug ...
Beyond the main headlines, European biotech kept moving this week. This edition of Meanwhile in Biotech covers an Alzheimer’s ...
Denmark's Genmab said adding its bispecific antibody petosemtamab to MSD's Keytruda (pembrolizumab) cut the risk of death by ...
Swiss pharma group Ferring Pharmaceuticals has agreed to acquire New York-based Gameto for up to $1.3825 billion (€1.24 ...
Switzerland-based Idorsia has launched a new pivotal Phase 3 trial of lucerastat in Fabry disease, targeting kidney deposits ...
Spanish biotech ALLOX has closed a €9.4 million ($10.5 million) seed round, led by Asabys with participation from Spanish and ...
Swiss DARPin specialist Molecular Partners is shifting its entire focus to radiopharmaceuticals and plans to cut up to 55 ...
Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...
Swedish private equity firm EQT wants to acquire diagnostics specialist Qiagen for €10.8 billion, or €46.50 per share. The company’s leadership unanimously supports the sale. Completion is planned for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results